CN103108652B - 嵌合OspA基因、蛋白以及其使用方法 - Google Patents

嵌合OspA基因、蛋白以及其使用方法 Download PDF

Info

Publication number
CN103108652B
CN103108652B CN201180033687.3A CN201180033687A CN103108652B CN 103108652 B CN103108652 B CN 103108652B CN 201180033687 A CN201180033687 A CN 201180033687A CN 103108652 B CN103108652 B CN 103108652B
Authority
CN
China
Prior art keywords
borrelia
ospa
polypeptide
seq
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180033687.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103108652A (zh
Inventor
布莱恩·A·克洛维
伊安·利维
马里亚·欧洛尔科
迈克尔·施文丁格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baishen Co
Baxalta GmbH
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of CN103108652A publication Critical patent/CN103108652A/zh
Application granted granted Critical
Publication of CN103108652B publication Critical patent/CN103108652B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201180033687.3A 2010-05-14 2011-05-13 嵌合OspA基因、蛋白以及其使用方法 Expired - Fee Related CN103108652B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
US61/334,901 2010-05-14
PCT/US2011/036525 WO2011143617A1 (en) 2010-05-14 2011-05-13 Chimeric ospa genes, proteins, and methods of use thereof

Publications (2)

Publication Number Publication Date
CN103108652A CN103108652A (zh) 2013-05-15
CN103108652B true CN103108652B (zh) 2016-05-11

Family

ID=44121257

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201180033687.3A Expired - Fee Related CN103108652B (zh) 2010-05-14 2011-05-13 嵌合OspA基因、蛋白以及其使用方法
CN201710853809.2A Expired - Fee Related CN107641151B (zh) 2010-05-14 2011-05-13 Ospa嵌合体及其在疫苗中的用途
CN201180033682.0A Expired - Fee Related CN103118701B (zh) 2010-05-14 2011-05-13 Ospa嵌合体及其在疫苗中的用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201710853809.2A Expired - Fee Related CN107641151B (zh) 2010-05-14 2011-05-13 Ospa嵌合体及其在疫苗中的用途
CN201180033682.0A Expired - Fee Related CN103118701B (zh) 2010-05-14 2011-05-13 Ospa嵌合体及其在疫苗中的用途

Country Status (13)

Country Link
US (6) US8623375B2 (enExample)
EP (4) EP2569008B1 (enExample)
JP (6) JP6030052B2 (enExample)
KR (7) KR20130062954A (enExample)
CN (3) CN103108652B (enExample)
AU (2) AU2011252850B2 (enExample)
BR (2) BR112012027315B1 (enExample)
CA (2) CA2799181C (enExample)
MX (3) MX348113B (enExample)
PL (2) PL2569009T3 (enExample)
RU (2) RU2636455C2 (enExample)
SI (2) SI2569008T1 (enExample)
WO (2) WO2011143617A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623375B2 (en) 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
US20120215701A1 (en) 2010-10-20 2012-08-23 Mehta Kaushal N Flexible monetization service apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
US10096022B2 (en) * 2011-12-13 2018-10-09 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2014018274A1 (en) * 2012-07-27 2014-01-30 Baxter International, Inc. Compositions comprising chimeric ospa molecules and methods of use thereof
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
WO2014144521A1 (en) * 2013-03-15 2014-09-18 The Regents Of The University Of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
US20160213766A1 (en) * 2013-09-23 2016-07-28 Ventria Bioscience, Inc. OspA Fusion Protein for Vaccination against Lyme Disease
MX369195B (es) 2014-01-09 2019-10-31 Valneva Austria Gmbh Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
EP3180024B1 (en) 2014-08-11 2022-05-18 University of Massachusetts Anti-ospa antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
WO2017029000A1 (en) * 2015-08-14 2017-02-23 Telefonaktiebolaget Lm Ericsson (Publ) A node and method for managing a packet data network connection
EP3534941A4 (en) * 2016-11-07 2020-07-08 The Wistar Institute Of Anatomy And Biology CONSTRUCTIONS OF ANTI-DNA ANTIBODIES FOR USE AGAINST LYME DISEASE
WO2018189372A1 (en) * 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
CN112584858A (zh) * 2018-04-03 2021-03-30 赛诺菲 抗原性ospa多肽
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
US20240026412A1 (en) 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
IL297166A (en) * 2020-04-09 2022-12-01 Valneva Austria Gmbh Compositions comprising three ospa fusion proteins for medical use
EP4262860A4 (en) 2020-12-17 2025-11-12 Idexx Lab Inc DETECTION AND TREATMENT OF ROCKY MOUNTAIN SPRINKLE FEVER
WO2022261050A1 (en) * 2021-06-07 2022-12-15 The University Of Massachusetts Apparatus and method for continuous production of rna
EP4490042A4 (en) 2022-03-08 2026-03-04 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM
JP2026525284A (ja) 2023-07-10 2026-07-29 ダイナヴァックス テクノロジーズ コーポレイション アジュバントおよびｂｏｒｒｅｌｉａ細胞表層タンパク質ａ抗原を含むライム病ワクチン
EP4743110A1 (en) 2023-07-10 2026-05-20 Dynavax Technologies Corporation Lyme disease vaccines containing an adjuvant and Borrelia outer surface protein A and C antigens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
WO2002016421A3 (en) * 2000-08-18 2003-03-06 Univ New York State Res Found Altered ospa of borrelia burgdorferi
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SG122738A1 (en) * 1990-06-15 2006-06-29 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
FI933580L (fi) 1991-02-15 1993-10-13 Uab Research Foundation Strukturgen av pneumokockprotein
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
WO2002016422A2 (en) * 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Recombinant constructs of borrelia burgdorferi
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
DE69433690T2 (de) 1993-11-01 2005-03-10 Brookhaven Science Associates Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
CA2244110A1 (en) 1996-02-12 1997-08-14 Cobra Therapeutics Limited Novel methods of vaccination and vaccines thereof comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
WO1999000413A1 (en) * 1997-06-30 1999-01-07 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
CN100351265C (zh) 2003-04-02 2007-11-28 美国政府健康及人类服务部 含胆固醇的化合物以及其用作针对伯氏疏螺旋体(Borrelia burgdorferi)的免疫原的应用
BRPI0409459A (pt) * 2003-04-16 2006-05-02 Wyeth Corp novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
ATE466022T1 (de) * 2004-03-24 2010-05-15 Merck Sharp & Dohme Optimierte expression von hpv-52-l1 in hefe
EP1768688A4 (en) 2004-07-02 2009-09-30 Raymond J Dattwyler ORAL BORRELIOSE VACCINE
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
AU2006320246A1 (en) 2005-11-29 2007-06-07 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
EP2289906A1 (en) 2006-09-15 2011-03-02 Intercell AG Borrelia antigens
ATE496935T1 (de) 2007-02-22 2011-02-15 Baxter Int Verfahren zur aufreinigung hydrophober proteine
EA200901578A1 (ru) * 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
JP5788676B2 (ja) * 2008-01-11 2015-10-07 イノビオ ファーマシューティカルズ，インコーポレイティド デングウイルスの複数のサブタイプに対する新規ワクチン
EP2274616A1 (en) 2008-04-22 2011-01-19 The Research Foundation of State University of New York Borrelia burgdorferi cell envelope protein array
WO2009135118A2 (en) 2008-05-02 2009-11-05 Virginia Commonwealth University Lyme disease vaccine
US8623375B2 (en) * 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
WO2014018274A1 (en) * 2012-07-27 2014-01-30 Baxter International, Inc. Compositions comprising chimeric ospa molecules and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
WO2002016421A3 (en) * 2000-08-18 2003-03-06 Univ New York State Res Found Altered ospa of borrelia burgdorferi
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii;Lise Gern et al;《vaccine》;19971001;第15卷(第4期);第1551-1557页 *

Also Published As

Publication number Publication date
BR112012027315B1 (pt) 2021-08-17
RU2012153972A (ru) 2014-06-20
US11305000B2 (en) 2022-04-19
AU2011252850A1 (en) 2012-11-29
PL2569009T3 (pl) 2020-06-15
CN103108652A (zh) 2013-05-15
JP2020178719A (ja) 2020-11-05
JP2018150386A (ja) 2018-09-27
KR20200084062A (ko) 2020-07-09
KR102230562B1 (ko) 2021-03-22
CN107641151A (zh) 2018-01-30
CN103118701A (zh) 2013-05-22
RU2012153752A (ru) 2014-06-20
WO2011143623A1 (en) 2011-11-17
JP6227407B2 (ja) 2017-11-08
EP3650041A1 (en) 2020-05-13
US9895434B2 (en) 2018-02-20
EP3705133A3 (en) 2021-01-06
CN107641151B (zh) 2021-10-01
US20120020973A1 (en) 2012-01-26
SI2569008T1 (sl) 2020-02-28
BR112012029058A2 (pt) 2020-06-23
MX340739B (es) 2016-07-22
US20160235830A1 (en) 2016-08-18
KR20180031814A (ko) 2018-03-28
KR20130133120A (ko) 2013-12-06
JP2016168057A (ja) 2016-09-23
WO2011143617A1 (en) 2011-11-17
AU2011252844B2 (en) 2014-07-03
RU2017138652A (ru) 2019-02-11
JP6965417B2 (ja) 2021-11-10
US20180296656A1 (en) 2018-10-18
US20110293652A1 (en) 2011-12-01
US9334311B2 (en) 2016-05-10
KR20130062954A (ko) 2013-06-13
MX348113B (es) 2017-05-29
EP3705133A2 (en) 2020-09-09
KR20190027955A (ko) 2019-03-15
MX375965B (es) 2025-03-07
BR112012029058B1 (pt) 2022-03-29
PL2569008T3 (pl) 2021-04-19
SI2569009T1 (sl) 2020-02-28
RU2636455C2 (ru) 2017-11-23
CA2799181C (en) 2023-10-24
AU2011252850B2 (en) 2016-03-17
BR112012027315A8 (pt) 2020-09-01
US20140141030A1 (en) 2014-05-22
CN103118701B (zh) 2017-10-24
JP2013529078A (ja) 2013-07-18
US8623376B2 (en) 2014-01-07
MX2012013261A (es) 2013-04-19
US20140141029A1 (en) 2014-05-22
JP2013529077A (ja) 2013-07-18
BR112012027315A2 (pt) 2016-11-16
MX2012013264A (es) 2014-12-05
EP2569008A1 (en) 2013-03-20
KR20200024354A (ko) 2020-03-06
CA2799181A1 (en) 2011-11-17
AU2011252844A1 (en) 2012-11-29
JP2016171816A (ja) 2016-09-29
US9303073B2 (en) 2016-04-05
US8623375B2 (en) 2014-01-07
RU2017138652A3 (enExample) 2021-03-15
CA2798331C (en) 2022-03-15
KR102222869B1 (ko) 2021-03-04
EP3705133B1 (en) 2024-06-26
EP2569009B1 (en) 2019-10-09
KR20180082633A (ko) 2018-07-18
EP2569008B1 (en) 2019-12-25
KR102085465B1 (ko) 2020-03-05
CA2798331A1 (en) 2011-11-17
EP2569009A1 (en) 2013-03-20
KR102130584B1 (ko) 2020-07-07
JP6030052B2 (ja) 2016-11-24
RU2583289C2 (ru) 2016-05-10

Similar Documents

Publication Publication Date Title
CN103118701B (zh) Ospa嵌合体及其在疫苗中的用途
US9023367B2 (en) Compositions comprising chimeric OSPA molecules and methods of use thereof
HK40029362A (en) Ospa chimeras and use thereof in vaccines
HK40029422A (en) Ospa chimeras and use thereof in vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160810

Address after: Illinois State

Patentee after: Baishen Co.

Patentee after: BAXALTA GmbH

Address before: Illinois State

Patentee before: Baxter International Inc.

Patentee before: BAXTER HEALTHCARE S.A.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160511